恩替卡韦联合百令胶囊治疗慢性乙型肝炎患者疗效初步研究

doi:10.3969/j.issn.1672-5069.2018.02.012

摘要/Abstract

摘要： 目的观察恩替卡韦联合百令胶囊治疗慢性乙型肝炎（CHB）患者的临床疗效。方法 A组127例CHB患者接受恩替卡韦,B组127例接受恩替卡韦和百令胶囊治疗,观察48 w疗效。结果在治疗24 w和48 w时,B组血清HBsAg水平为（3.2±0.3） lg IU/mL和（3.3±0.4） lg IU/mL,显著低于A组的（3.7±0.4） lg IU/mL和（3.6±0.5） lg IU/mL（P<0.05）,HBeAg水平为（1.6±0.2） lg PEIU/L和（1.4±0.1） lg PEIU/L,显著低于A组的（1.8±0.2） lg PEIU/L和（1.6±0.3） lg PEIU/L（P<0.05）;血清谷丙转氨酶（ALT）、乳酸脱氢酶（LDH）、谷草转氨酶（AST）和腺苷脱氨酶（ADA）水平显著低于A组（P<0.05）;血清肌酐（sCr）、胱抑素C（Cys C）和尿素氮（BUN）水平显著低于A组（P<0.05）;肝细胞色素P450亚型酶中的药物代谢酶CYP2E1、CYP2C9和CYPIA2水平显著低于A组（P<0.05）;血清肌酸磷酸激酶（CPK）和丙二醛（MDA）显著低于A组（P<0.05）;还原型谷胱甘肽（GSH）和超氧化物歧化酶（SOD）显著高于A组（P<0.05）;两组血清HBV DNA载量无显著性差异（P>0.05）。结论百令胶囊可降低恩替卡韦治疗CHB患者出现肾功能损伤的风险。

关键词: 慢性乙型肝炎, 恩替卡韦, 百令胶囊, 肾功能损伤

Abstract: Objective To observe the clinical efficacy of entecavir combined with Bailing capsule in the treatment of patients with chronic hepatitis B. Methods 254 patients with CHB were randomly divided into group A and group B （n=127）. Patients in group A was treated with entecavir,and patients in group B was treated with entecavir combined with Bailing capsule. Results At the end of 24 w and 48 w treatment,serum HBsAg levels in group B were （3.2±0.3） lg IU/mL and （3.3±0.4） lg IU/mL,significantly lower than in group A （3.7±0.4）lg IU/mL and （3.6±0.5）lg IU/mL （P<0.05）;serum HBeAg levels were （1.6±0.2） lg PEIU /mL and （1.4±0.1）lg PEIU /mL,significantly lower than in group A（1.8±0.2） lg PEIU/mL and（1.6±0.3） lg PEIU/L（P<0.05）;serum alanine aminotransferase,lactate dehydrogenase（LDH）,aspartate aminotransferase and adenosine deaminase（ADA） levels were significantly lower than in group A（P<0.05）;serum creatinine,cystatin C and urea nitrogen levels were significantly lower than in group A（P<0.05）;cytochrome P450 isoforms,e.g. CYP2E1,CYP2C9 and CYPIA2 were significantly lower than in group A（P<0.05）;serum creatine kinase and MDA levels were significantly lower than in group A （P<0.05）;serum glutathione （GSH） and superoxide dismutase （SOD） were significantly higher than in group A P<0.05）;serum HBV DNA loads in the two groups had no significant difference（P>0.05）. Conclusion Bailing capsule can reduce the risk of renal damage of entecavir in the treatment of patients with CHB.

Key words: Hepatitis B, Entecavir, Bailing capsule, Kidney damage

杨莎莎, 周利. 恩替卡韦联合百令胶囊治疗慢性乙型肝炎患者疗效初步研究[J]. 实用肝脏病杂志, 2018, 21(2): 204-207.

Yang Shasha, Zhou Li. Combination of entecavir and Bailing capsule in treatment of patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 204-207.

参考文献

[1] Keating GM.Entecavir:a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs,2011,71(18):2511-2529.
[2] 赵玉倩,许杏梅,杨慧娟,等. 恩替卡韦联合六味五灵片治疗慢性乙型肝炎患者疗效观察. 实用肝脏病杂志,2016,l9(1):83-85.
[3] 陈雅萍,张勤俭,田楠楠. 恩替卡韦联合聚乙二醇干扰素治疗慢性乙型肝炎患者疗效观察. 实用肝脏病杂志,2016,l9(2):208-209.
[4] 左琳琳,周华娟,方红菊. 恩替卡韦治疗46 例失代偿期乙型肝炎肝硬化患者临床效果观察. 实用肝脏病杂志,2016,19(2):217-218.
[5] 张骏飞,刘波,陈从新,等. 含毗咯烷生物碱的中草药致肝窦阻塞综合征研究进展. 实用肝脏病杂志,2014,17(4):445-448.
[6] Liaw YF, Sheen IS,Lee CM,et al.Tenofovir disoproxil fumarate (TDF),emtricitabine/TDF,and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology,2011,53(1):62-72.
[7] Papatheodoridis GV,Chan HL,Hansen BE,et al.Risk of hepatocellular carcinoma in chronic hepatitis B:Assessment and modification with current antiviral therapy. J Hepatol,2015,62(4):956-967.
[8] Seto WK,Hui AJ,Wong VW,et al.Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B:a multicentre prospective study. Gut,2015,64(4):667-667.
[9] Dienstag JL,Wei LJ,Xu D, et al.Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients.Clin Drug Investig,2007,27(1):35-49.
[10] Lok AS,Trinh H,Carosi G,et al.Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B.Gastroenterology,2012,143(3):619-628.
[11] Cai S,Yu T,Jiang Y,et al.Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load:48-week result. Clin Exp Med,2016,16(3):429-436.
[12] Deng CL,Song XW,Liang HJ,et al.Chronic hepatitis B serum promotes apoptotic damage in human renal tubular cells.World J Gastroenterol,2006,12(11):1752-1756.
[13] Zheng JS,Chen MM,Yang HF,et al.Stool vs. serum hepatitis B virus DNA in patients with chronic hepatitis B. Med Sci Monit,2015,21(3):3840-3846.
[14] You J,Sriplung H,Geater A,et al.Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. World J Gastroenterol,2008,14(7):1112-1119.
[15] Yu X,Guo R,Ming D,et al.Ratios of regulatory T cells/T-helper 17 cells and transforming growth factor-1/interleukin-17 to be associated with the development of hepatitis B virus-associated liver cirrhosis. J Gastroenterol Hepatol,2014 ,29(5):1065-1072.
[16] Yim SY,Um SH,Young Jung J,et al.Clinical significance of hepatitis B virus precore and core promoter variants in Korean patients with chronic hepatitis B. J Clin Gastroenterol,2015,49(1):61-68.
[17] Li F,Wei H,Wei H,et al.Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice.Gastroenterology,2013,144(2):392-401.
[18] Madan K,Batra Y,Jha JK,et al.Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection.Trop Gastroenterol,2008,29(2):84-90.
[19] Assy N,Beniashvili Z,Djibre A,et al.Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg-chronic hepatitis B patients from inactive chronic carriers. World J Gastroenterol,2009,15(24):3025-3031.
[20] 蒋俊民,萧焕明,蔡高术,等. 慢性乙型肝炎中医诊疗方案的优化研究. 中国中医急症,2012,21(12):1901-1904.
[21] 李龙珠,刘家军,郭俐宏,等. 百令胶囊对大鼠肝移植后肝肾功能影响的实验研究. 世界中医药,2016,11(1):127-130.
[22] 杨娥,李小燕,杨萍,等.丹参酮ⅡA磺酸钠注射液联合百令胶囊治疗肾血管性高血压的疗效观察. 现代药物与临床,2016,12(3):315-319.